Tirzepatide in cardiovascular disease

New guidelines and consensus this year

1. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society
   Maturitas2026 Oct
2. Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)
   Ann Intern Med2026 Aug
3. Swiss obesity clinical practice guidance
   Swiss Med Wkly2026 May 19
4. [Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)]
   Wien Klin Wochenschr2026 May
5. Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach
   Obesity (Silver Spring)2026 Apr

1. Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
   J Diabetes Metab Disord2026 DecPMID 42840232
2. Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program
   Am J Prev Cardiol2026 DecPMID 42828252
3. Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study
   Int J Cardiol2026 Dec 1PMID 42710812
4. Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
   J Med Econ2026 DecPMID 42012820
5. Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing
   Eur J Pharmacol2026 Nov 25PMID 42826814
6. Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy
   J Endocr Soc2026 NovPMID 42857401Review
7. Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity
   J Diabetes Complications2026 NovPMID 42805130
8. Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications
   Curr Opin Nephrol Hypertens2026 Nov 1PMID 42683763Review
9. From adiposity to multisystem morbidity: the case for weight loss as disease modification
   Lancet Diabetes Endocrinol2026 NovPMID 42660161Review
10. Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation
    Diabetes Obes Metab2026 NovPMID 42642357